MorphoSys Strengthens Patent Position on Lead Program MOR103
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Strengthens Patent Position on Lead Program MOR103
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the
US Patent and Trademark Office (USPTO) has granted a patent covering the
Company's most advanced proprietary compound MOR103. The new patent (US
7,867,495) covers MorphoSys's HuCAL antibody against GM-CSF as well as
pharmaceutical compositions comprising the same, and has a scheduled expiry date
in 2026, not including any potential extensions.
This newly issued patent complements a US patent granted in 2008 covering
medical uses of antibodies against GM-CSF, to which MorphoSys has exclusive
access under a license agreement with the University of Melbourne. Together, the
two patent families provide strong intellectual property protection for the
MOR103 program.
"The protection of our intellectual property is a central part of MorphoSys's
business model," commented Dr. Simon Moroney, Chief Executive Officer of
MorphoSys AG. "We will continue to strengthen still further our intellectual
property position in antibody-based products and services, particularly in our
most important markets Europe, the USA and Asia."
Human GM-CSF (Granulocyte macrophage-colony stimulating factor), the target
molecule of MorphoSys's lead program MOR103, is implicated in a number of
inflammatory and other conditions including rheumatoid arthritis (RA) and
multiple sclerosis (MS). The HuCAL-derived, fully human antibody is currently
being tested in a clinical Phase 1b/2a trial in RA patients. Additionally,
MorphoSys plans to start a Phase 1b safety study of MOR103 in multiple sclerosis
patients in 2011.
Currently, the Company is prosecuting more than 40 different proprietary patent
families world-wide, in addition to those being pursued in cooperation with its
partners.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visit http://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys; arYla(TM) is a trademark of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release:
http://hugin.info/130295/R/1485502/420654.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1485502]
Unternehmensinformation / Kurzprofil:
Datum: 07.02.2011 - 07:31 Uhr
Sprache: Deutsch
News-ID 51124
Anzahl Zeichen: 6333
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 178 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Strengthens Patent Position on Lead Program MOR103"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
